CL2022000990A1 - Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1 - Google Patents

Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1

Info

Publication number
CL2022000990A1
CL2022000990A1 CL2022000990A CL2022000990A CL2022000990A1 CL 2022000990 A1 CL2022000990 A1 CL 2022000990A1 CL 2022000990 A CL2022000990 A CL 2022000990A CL 2022000990 A CL2022000990 A CL 2022000990A CL 2022000990 A1 CL2022000990 A1 CL 2022000990A1
Authority
CL
Chile
Prior art keywords
combination
cxcr7
receptor modulator
cxcr7 antagonist
antagonist
Prior art date
Application number
CL2022000990A
Other languages
English (en)
Inventor
Laetitia Pouzol
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2022000990A1 publication Critical patent/CL2022000990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuesto (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico y su uso como modulador del receptor de CXCL11/CXCL12, CXCR7, en combinación con otros ingredientes o agentes, en la prevención o tratamiento de enfermedades y trastornos donde tanto la expresión de CXCR7 o sus ligandos y S1P desempeñan una función. Composiciones farmacéuticas que comprenden el compuesto.
CL2022000990A 2019-10-31 2022-04-20 Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1 CL2022000990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019079932 2019-10-31

Publications (1)

Publication Number Publication Date
CL2022000990A1 true CL2022000990A1 (es) 2023-01-27

Family

ID=75715765

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000990A CL2022000990A1 (es) 2019-10-31 2022-04-20 Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1

Country Status (11)

Country Link
EP (1) EP4051250A1 (es)
JP (1) JP2023501217A (es)
KR (1) KR20220093330A (es)
CN (1) CN114599363A (es)
AU (1) AU2020372647A1 (es)
CA (1) CA3156298A1 (es)
CL (1) CL2022000990A1 (es)
IL (1) IL292529A (es)
MX (1) MX2022005014A (es)
TW (1) TW202131921A (es)
WO (1) WO2021084068A1 (es)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ATE483698T1 (de) 2003-11-21 2010-10-15 Actelion Pharmaceuticals Ltd 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
CA2589265A1 (en) 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
ES2378776T3 (es) 2004-12-13 2012-04-17 Ono Pharmaceutical Co., Ltd. Derivado de ácido aminocarboxílico y uso medicinal del mismo
KR101346527B1 (ko) 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP4669564B2 (ja) 2006-11-23 2011-04-13 アクテリオン ファーマシューティカルズ リミテッド ２−イミノ−チアゾリジン−４−オン誘導体の製造のための新規な方法
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
BRPI0910236A2 (pt) 2008-03-24 2019-09-24 Kyorin Seiyaku Kk método para cristalização de composto
KR20190132565A (ko) 2008-07-23 2019-11-27 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
KR20130109254A (ko) 2008-11-11 2013-10-07 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
CN105198760A (zh) 2008-11-11 2015-12-30 诺华股份有限公司 芬戈莫德的盐
KR20110096584A (ko) 2008-12-18 2011-08-30 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
RU2011129230A (ru) 2008-12-18 2013-01-27 Новартис Аг Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
NZ593427A (en) 2008-12-22 2013-11-29 Novartis Ag Dosage regimen of an s1p receptor agonist
UY32352A (es) 2008-12-22 2010-07-30 Novartis Ag Régimen de dosificación para un agonista de los receptores de s1p
BR112012000763B8 (pt) 2009-07-16 2021-05-25 Actelion Pharmaceuticals Ltd compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto
MX2012003752A (es) 2009-09-29 2012-06-01 Novartis Ag Metodo y sistema para accesar datos de pacientes.
TR201807912T4 (tr) 2009-11-13 2018-06-21 Celgene Int Ii Sarl Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇.
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
US20150218090A1 (en) 2011-10-21 2015-08-06 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
US20150133669A1 (en) 2012-05-22 2015-05-14 Actelion Pharmaceuticals Ltd. New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
EP3062792A1 (en) 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
TW201622721A (zh) 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
CN117137912A (zh) 2014-12-11 2023-12-01 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
EA035133B1 (ru) 2015-05-20 2020-04-30 Идорсия Фармасьютиклз Лтд Кристаллическая форма соединения (s)-3-{4-[5-(2-циклопентил-6-метоксипиридин-4-ил)-[1,2,4]оксадиазол-3-ил]-2-этил-6-метилфенокси}пропан-1,2-диола
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
PT3798217T (pt) 2016-07-28 2023-05-23 Idorsia Pharmaceuticals Ltd Moduladores do recetor de piperidina cxcr7
ES2925280T3 (es) 2016-07-29 2022-10-14 Mitsubishi Tanabe Pharma Corp Método de producción de alcohol 4-alcoxi-3-(trifluorometil)bencílico
US20200031784A1 (en) 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
US11207301B2 (en) 2017-05-08 2021-12-28 Receptos Llc Sphingosine 1 phosphate receptor agonists for neuroprotection
PL3630738T3 (pl) 2017-05-22 2024-04-08 Egis Gyógyszergyár Zrt. Sposób wytwarzania ozanimodu
WO2019058290A1 (en) 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
JP2020535175A (ja) 2017-09-27 2020-12-03 ドクター レディズ ラボラトリーズ リミテッド シポニモド、その塩およびその固体状態フォームの調製のためのプロセス
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
MA51664A (fr) 2018-01-26 2021-05-05 Idorsia Pharmaceuticals Ltd Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide

Also Published As

Publication number Publication date
CA3156298A1 (en) 2021-05-06
KR20220093330A (ko) 2022-07-05
IL292529A (en) 2022-06-01
TW202131921A (zh) 2021-09-01
MX2022005014A (es) 2022-05-16
AU2020372647A1 (en) 2022-06-16
JP2023501217A (ja) 2023-01-18
EP4051250A1 (en) 2022-09-07
WO2021084068A1 (en) 2021-05-06
CN114599363A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
CO2020009625A2 (es) Inhibidor de fap
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
UY37831A (es) Nuevos derivados de quinolina
CO2019014484A2 (es) Nuevos derivados de azaquinolina
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
EA200801997A1 (ru) Новые соединения
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2020002891A1 (es) Nuevos derivados de quinolina
MX2022002183A (es) Composiciones de éster de ácido cannabinoide y sus usos.
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
BR112021017037A2 (pt) Composição farmacêutica contendo acetaminofeno e ibuprofeno
JOP20220045A1 (ar) تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.
CL2007001794A1 (es) Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
PL416198A1 (pl) Kompozycja farmaceutyczna zawierająca połączenie kwasu hialuronowego i roślinnych fitoestrogenów do aplikacji waginalnej